Atnaujinkite slapukų nuostatas

Biocompatibility and Performance of Medical Devices [Kietas viršelis]

Edited by (Biomatech, France)
  • Formatas: Hardback, 544 pages, aukštis x plotis: 234x156 mm, weight: 980 g
  • Serija: Woodhead Publishing Series in Biomaterials
  • Išleidimo metai: 26-Oct-2012
  • Leidėjas: Woodhead Publishing Ltd
  • ISBN-10: 0857090704
  • ISBN-13: 9780857090706
Kitos knygos pagal šią temą:
  • Formatas: Hardback, 544 pages, aukštis x plotis: 234x156 mm, weight: 980 g
  • Serija: Woodhead Publishing Series in Biomaterials
  • Išleidimo metai: 26-Oct-2012
  • Leidėjas: Woodhead Publishing Ltd
  • ISBN-10: 0857090704
  • ISBN-13: 9780857090706
Kitos knygos pagal šią temą:
Implant and device manufacturers are increasingly facing the challenge of proving that their products are safe and biocompatible, and that they will perform as expected. Biocompatibility and performance of medical devices provides an essential guide to the performance analysis of these vital devices.Part one introduces the key concepts and challenges faced in relation to biocompatibility in medical devices, with consideration of biological safety evaluation planning and biomechanical and biochemical compatibility in innovative biomaterials. Part two goes on to discuss the evaluation and characterisation of biocompatibility in medical devices. Topics covered include material and chemical characterisation, allowable limits for toxic leachables, in vivo and in vitro testing and blood compatibility assessment. Testing and interpreting medical device performance is the focus of part three, with chapters describing preclinical performance studies for bone, dental and soft tissue implants, and mechanical testing of soft and hard tissue implants. Part four provides information on the regulation of medical devices in the European Union, Japan and China, and the book concludes with part five, a review of histopathology principles for biocompatibility and performance studies.With its distinguished editor and international team of expert contributors, Biocompatibility and performance of medical devices is a vital tool for all those involved in the research, design, production and application of medical devices, including research directors, production companies and medical regulatory agencies, as well as industry professionals and academics.

Recenzijos

"Multiple authors have come together to present their views on the best options, the best techniques and the optimal methods of interpretation of data. Expertly assembled by Jean-Pierre Boutrand the contents of this book will allow the reader to attain an insight into the complexities of this testing arena." --Professor David Williams, Wake Forest Baptist Medical Center, USA (from the Foreword)

Contributor contact details xiii
Woodhead Publishing Series in Biomaterials xvii
Foreword xxi
Introduction xxiii
Part I Introduction to biocompatibility in medical devices
1(62)
1 Concepts in biocompatibility: new biomaterials, new paradigms and new testing regimes
3(15)
D. Williams
1.1 Introduction: traditional biomaterials and biocompatibility test procedures
3(3)
1.2 The evolution from implantable medical devices to regenerative medicine and bionanotechnology
6(2)
1.3 New concepts and definitions for biocompatibility
8(5)
1.4 A proposed conceptual framework for new biocompatibility concepts and testing regimes
13(3)
1.5 Conclusions and future trends
16(1)
1.6 References
17(1)
2 Challenges in biocompatibility and failure of biomaterials
18(12)
R. Eloy
2.1 Introduction
18(1)
2.2 Concept of biocompatibility
19(3)
2.3 Examples of device recalls or alerts during the last decade in which biocompatibility issues were considered
22(3)
2.4 Challenges in biocompatibility evaluation
25(3)
2.5 Conclusion
28(1)
2.6 References
29(1)
3 Biological safety evaluation planning of biomaterials
30(7)
D. Parente
3.1 Introduction
30(1)
3.2 The fundamentals of safety evaluation planning
30(2)
3.3 Safety evaluation planning for biomaterials
32(1)
3.4 Developing and documenting plans
33(1)
3.5 Using safety evaluations
34(1)
3.6 Conclusion
35(1)
3.7 Sources of further information and advice
36(1)
4 Biomechanical and biochemical compatibility in innovative biomaterials
37(26)
J. Huang
Z. X. Guo
4.1 Introduction
37(1)
4.2 Selection of biomaterials
38(2)
4.3 Three generations of biomedical materials
40(1)
4.4 State-of-the-art development
41(9)
4.5 Future trends
50(4)
4.6 Conclusion
54(2)
4.7 References
56(7)
Part II Evaluation and characterisation of biocompatibility in medical devices
63(206)
5 Material and chemical characterization for the biological evaluation of medical device biocompatibility
65(30)
D. E. Albert
5.1 Introduction
65(1)
5.2 Background
66(3)
5.3 Requirements of ISO 10993
69(2)
5.4 Characterization of materials
71(3)
5.5 Chemical characterization of extracts
74(7)
5.6 Using chemical and material characterization to demonstrate equivalency
81(3)
5.7 Acceptance criteria for equivalency
84(2)
5.8 Risk assessment of extracts
86(6)
5.9 Conclusion and future trends
92(1)
5.10 References
93(2)
6 Allowable limits for toxic leachables: practical use of ISO 10993-17 standard
95(25)
R. P. Brown
6.1 Introduction
95(3)
6.2 Process for setting tolerable intake (TI) values for compounds released from medical device materials
98(5)
6.3 Derivation of non-cancer TI values
103(5)
6.4 Derivation of cancer-based TI values
108(3)
6.5 Derivation of TI values for local effects
111(1)
6.6 Other issues to consider
112(2)
6.7 Conclusion
114(1)
6.8 References
115(5)
7 In vivo and in vitro testing for the biological safety evaluation of biomaterials and medical devices
120(39)
W. H. De Jong
J.W. Carraway
R. E. Geertsma
7.1 Introduction
120(1)
7.2 Pre-testing considerations
121(5)
7.3 Sample preparation
126(1)
7.4 In vitro testing
127(9)
7.5 In vivo testing
136(21)
7.6 Conclusion
157(1)
7.7 References
157(2)
8 Practical approach to blood compatibility assessments: general considerations and standards
159(42)
M. F. Wolf
J. M. Anderson
8.1 Introduction
159(1)
8.2 Background: blood composition
160(7)
8.3 Critical distinguishing factors presented by blood-contacting medical devices
167(6)
8.4 Responses in fluid blood in contact with medical devices
173(4)
8.5 Responses by materials, or upon their surfaces, in contact with blood
177(8)
8.6 Assessing hemocompatibility according to international standards
185(8)
8.7 Conclusion and future trends
193(1)
8.8 Sources of further information and advice
194(2)
8.9 References
196(5)
9 Medical device biocompatibility evaluation: an industry perspective
201(26)
K. Coleman
X. Dai
X. Deng
F. Lakehal
X. Tang
9.1 Introduction
201(1)
9.2 Developing a biological evaluation plan
202(2)
9.3 Implementing a biological evaluation plan
204(3)
9.4 Biological safety testing
207(3)
9.5 Creating a biological evaluation report
210(2)
9.6 Conclusion and future trends
212(3)
9.7 Sources of further information and advice
215(6)
9.8 References
221(3)
9.9 Appendix: example of a material component biological evaluation report template
224(3)
10 Case study: overcoming negative tests results during manufacture
227(6)
D. Parente
10.1 Introduction
227(1)
10.2 Cardio Medical: a fictitious case study
228(1)
10.3 The biological safety program
229(1)
10.4 Extractables and leachables
229(1)
10.5 Controlling risk at the manufacturing level
230(1)
10.6 Sterilization residuals
231(1)
10.7 Conclusion
232(1)
11 Methods for the characterisation and evaluation of drug-device combination products
233(36)
A. L. Lewis
11.1 Introduction to combination products
233(1)
11.2 Combination product regulation
234(1)
11.3 Demonstrating safety and efficacy of combination products
235(2)
11.4 Pre-clinical testing of combination products
237(21)
11.5 Aspects to consider in the manufacture of combination products
258(3)
11.6 Clinical studies for combination products
261(2)
11.7 Conclusion and future trends
263(1)
11.8 References
264(5)
Part III Testing and interpreting the performance of medical devices
269(112)
12 Methods and interpretation of performance studies for bone implants
271(37)
J.-P. Boutrand
12.1 Introduction
271(1)
12.2 Definitions
272(2)
12.3 Scope
274(1)
12.4 Principles for the selection of an in vivo model to evaluate performance of bone implants
275(4)
12.5 Designing a study to evaluate performance of bone implants
279(3)
12.6 Selection of reference products and controls
282(3)
12.7 Osteoinductive and osteogenic performances
285(1)
12.8 In vitro limitations
286(2)
12.9 Fracture repair models
288(4)
12.10 Spinal fusion models
292(2)
12.11 Cylindrical defect models
294(1)
12.12 Segmental defect models
295(1)
12.13 Antimicrobial performances of implants
296(1)
12.14 Bioabsorbable and biodegradable materials
297(1)
12.15 Bone debris interaction with implant performance
298(1)
12.16 Conclusion
299(2)
12.17 References
301(7)
13 Methods and interpretation of performance studies for dental implants
308(37)
M. Dard
13.1 Introduction and definitions
308(1)
13.2 Importance of performance evaluation studies for dental implants
309(2)
13.3 Experimental design of a performance trial for dental implants
311(9)
13.4 Choice of model
320(3)
13.5 Statistical power calculation and analysis
323(3)
13.6 Analysis
326(11)
13.7 Translation from animal studies to human clinical trials
337(1)
13.8 Acknowledgments
337(1)
13.9 Sources of further information and advice
338(1)
13.10 References
338(7)
14 Non-clinical functional evaluation of medical devices: general recommendations and examples for soft tissue implants
345(17)
G. Clermont
14.1 Introduction and definitions
345(1)
14.2 The purpose of functional studies
346(2)
14.3 Standards and documentation
348(1)
14.4 How to design a functional study
349(8)
14.5 Combining non-clinical functional studies with requirements of safety standards
357(1)
14.6 Conclusion
358(1)
14.7 References
359(3)
15 Mechanical testing for soft and hard tissue implants
362(19)
C. Kaddick
15.1 Introduction
362(1)
15.2 Principles of setting up a mechanical test
363(5)
15.3 Implant-specific mechanical performance testing
368(7)
15.4 Advanced therapy products (ATPs) - cartilage
375(2)
15.5 Conclusion and future trends
377(1)
15.6 Sources of further information and advice
377(1)
15.7 References
378(3)
Part IV International regulation of medical devices
381(74)
16 Biological evaluation and regulation of medical devices in the European Union
383(21)
A.T. Keene
16.1 Introduction
383(1)
16.2 The regulatory and legislative framework
383(2)
16.3 Essential requirements
385(3)
16.4 Presumption of conformity
388(1)
16.5 Using the EN ISO 10993 series of standards to meet the essential requirements
389(2)
16.6 The notified body
391(4)
16.7 Common pitfalls in biological evaluations
395(4)
16.8 Managing positive results in the biological safety assessment
399(1)
16.9 Presenting the biological evaluation within the technical file
400(1)
16.10 Conclusion
401(1)
16.11 Sources of further information and advice
401(1)
16.12 Appendix: model content of the biological evaluation submission
401(3)
17 Biological evaluation and regulation of medical devices in Japan
404(45)
K. Kojima
17.1 Introduction
404(1)
17.2 Outline of biological safety testing in Japan
405(3)
17.3 Biological safety tests
408(32)
17.4 Relationship and comparison between the International Organization for Standardization (ISO) standard and American Society for Testing and Materials (ASTM) standard
440(2)
17.5 Relationship between classification, examination, and certification in Japan
442(2)
17.6 Outline of the medical device Good Laboratory Practice (GLP)
444(1)
17.7 Conclusion
444(2)
17.8 References
446(3)
18 Medical device regulations in China
449(6)
S. Likui
18.1 Introduction
449(1)
18.2 Interpretation of ISO 10993 and additional State Food and Drug Administration (SFDA) requirements
449(3)
18.3 Major professional bodies
452(2)
18.4 References
454(1)
Part V Histopathology principles for biocompatibility and performance studies
455(46)
19 Microscopic and ultrastructural pathology in medical devices
457(44)
A. Alves
J. Render
19.1 Introduction
457(2)
19.2 Morphologic assessment in the safety studies of biomaterials and medical devices
459(9)
19.3 Assessment of the performance of biomaterials and medical devices
468(7)
19.4 Processing and sectioning of specimens
475(3)
19.5 Staining recommendations
478(1)
19.6 Qualitative and quantitative pathology used in the evaluation of biomaterials and medical devices
479(4)
19.7 Ultrastructural pathology
483(5)
19.8 Morphologic assessment of ocular medical devices
488(6)
19.9 Conclusion
494(1)
19.10 Acknowledgments
495(1)
19.11 References
496(5)
Index 501
Jean-Pierre Boutrand is General Manager and Scientific Director for the European division of NAMSA (the world leading medical device evaluation company). Dr Boutrand has been involved in more than 100 public presentations and publications on topics related to medical device evaluation and is registered as an expert on the biological safety of medical devices for ANSM (the French agency for the safety of health products).